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OBJECTIVE — Theaimofthisstudywastodeterminewhetherlong-termcardiovascularrisk
differs in type 2 diabetic patients compared with ﬁrst acute myocardial infarction patients in a
Mediterranean region, considering therapy, diabetes duration, and glycemic control.
RESEARCH DESIGN AND METHODS — A prospective population-based cohort study
with 10-year follow-up was performed in 4,410 patients aged 30–74 years: 2,260 with type 2
diabetes without coronary heart disease recruited in 53 primary health care centers and 2,150 with
ﬁrst acute myocardial infarction without diabetes recruited in 10 hospitals. We compared coronary
heart disease incidence and cardiovascular mortality rates in myocardial infarction patients and
diabetic patients, including subgroups by diabetes treatment, duration, and A1C.
RESULTS — The adjusted hazard ratios (HRs) for 10-year coronary heart disease incidence
and for cardiovascular mortality were signiﬁcantly lower in men and women with diabetes than
in myocardial infarction patients: HR 0.54 (95% CI 0.45–0.66) and 0.28 (0.21–0.37) and 0.26
(0.19–0.36) and 0.16 (0.10–0.26), respectively. All diabetic patient subgroups had signiﬁ-
cantly fewer events than myocardial infarction patients: the HR of cardiovascular mortality
rangedfrom0.15(0.09–0.26)to0.36(0.24–0.54)andthatofcoronaryheartdiseaseincidence
ranged from 0.34 (0.26–0.46) to 0.56 (0.43–0.72).
CONCLUSIONS — Lowerlong-termcardiovascularriskwasfoundintype2diabeticandall
subgroupsanalyzedcomparedwithmyocardialinfarctionpatients.Theseresultsdonotsupport
equivalence in coronary disease risk for diabetic and myocardial infarction patients.
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T
heprevalenceofdiabetesisreaching
epidemic proportions in developed
countries (1). For example, the U.S.
has18milliondiabeticpatients,Spainhas
2 million diabetic patients, and man-
agement of the disease costs $132 and
$3.3 billion per year, respectively (2).
Some studies (3–5), several of them
with great inﬂuence on important guide-
lines for cardiovascular prevention (3),
suggest that the cardiovascular risk of di-
abetic patients is similar to that of coro-
nary heart disease secondary prevention
patients. Other reports, however, do not
conﬁrm these observations (6–10).
Part of the discrepancy may stem
from differences in the duration of diabe-
tes, type of treatment, and baseline glu-
cose control of diabetic patients included
in the studies (3–5). These limit compa-
rability, given the fact that time of evolu-
tion and treatment required to attain
appropriate glycemic control are key de-
terminants of prognosis (10–16).
Among population-based cohort
studies that compared the prognosis of
diabetic patients with that of myocardial
infarction patients without diabetes (3–
10),onlytwoanalyzedtheroleofdiabetes
duration (11,12). Even these studies did
not include unstable angina among the
end points and risk was not stratiﬁed by
type of treatment. To our knowledge, the
effectoftype2diabetesoncoronaryheart
disease incidence has barely been studied
in southern Europe, a region known for
low cardiovascular mortality (17). The
aim of this study was to determine
whether long-term cardiovascular risk
differed between type 2 diabetic patients
and ﬁrst acute myocardial infarction pa-
tientsandtoassesstheinﬂuenceofdiabe-
tes duration, type of treatment, and
glycemic control at baseline.
RESEARCH DESIGN AND
METHODS— We designed a cohort
study in Catalonia (northeast Spain) that
included two groups of patients aged
30–74years:consecutiveﬁrstacutemyo-
cardial infarction patients without diabe-
tes who survived at least 28 days after
indexmyocardialinfarctionsymptomon-
set and a random sample of type 2 dia-
betic patients without coronary heart
disease. The study was approved by a lo-
cal ethics committee (Institut Municipal
d’Investigacio ´M e `dica)andcompliedwith
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guidelines (Declaration of Helsinki).
Acute myocardial infarction patients
were recruited consecutively between
1990 and 2003 in the context of the pop-
ulation-based REGICOR (Registre Gironí
del Cor [Girona Heart Registry]) study
(17). The reference population was
600,000 individuals. All 10 public and
private hospitals in the region participate
inREGICOR,usingthesamestandardsto
diagnose acute myocardial infarction:
non–Q-wave and Q-wave myocardial in-
farction, determined by a discharge elec-
trocardiogram in patients who presented
with chest pain lasting 20 min on ad-
mission, followed by typical changes in
serial electrocardiograms and an abnor-
mal increase in the cardiac enzymes or
troponin value curve.
We excluded patients outside the se-
lected age range and those meeting the
National Diabetes Data Group 1979 and
American Diabetes Association 1997 cri-
teria for diabetes (18,19), including pa-
tientswithtwoconsecutivefastingplasma
glucosevalues7.8or7mmol/lduring
admission, before and after 1998, previ-
ous acute myocardial infarction, or other
diseases that shortened life expectancy to
1 year.
Type 2 diabetic patients were ran-
domly recruited between 1993 and 1998
in the 53 primary health care centers in
Catalonia participating in the GEDAPS
(GrupodeEstudiodelaDiabetesenAten-
cio ´n Primaria de Salud [Primary Health
Care Diabetes Study Group]) network.
The total adult population attending the
participating primary health care centers
was982,567.Diagnosisoftype2diabetes
was based on National Diabetes Data
Group 1979 criteria, i.e., two fasting
plasma glucose values 7.8 mmol/l or
2-h plasma glucose values 11.1 mmol/l
during oral glucose tolerance test (18).
We excluded patients not within the age
range of the study, with BMI 22 kg/m
2,
diseases that shortened life expectancy to
1 year or history of any coronary heart
event or ketoacidosis.
Baseline study
For all participants, we recorded age, sex,
follow-up (in days), and, from medical
records, their history of dyslipidemia and
hypertension and smoking habit. For di-
abeticpatientswealsocollectedA1Ccon-
centration (fructosamine levels were not
considered), treatment (diet, oral drugs,
or insulin), and duration of diabetes in
years. In acute myocardial infarction pa-
tients, the presence of a Q-wave in the
electrocardiogram was recorded.
Follow-up and end points
In 2008, we completed up to 10 years
follow-up by telephone, medical exami-
nation, or clinical record review. Partici-
pating physicians veriﬁed all clinical
record events. We also cross-linked our
databases with the ofﬁcial Mortality Reg-
istry of Catalonia.
The individual end points considered
were all-cause death, coronary death,
stroke death, cardiovascular death, non-
fatal acute myocardial infarction, and un-
stable angina. Two composite end points
were used in the analyses: cardiovascular
mortality (coronary, stroke, and other
cardiovascular deaths) and coronary
heart disease incidence (unstable angina
or fatal or nonfatal acute myocardial in-
farction). The ﬁrst cardiovascular event,
regardless of its severity, was considered
in the analysis.
Deaths were considered of coronary
heart disease origin in cases of suggestive
necropsyﬁndings,clinicalrecordsofhos-
pitalized patients, or the presence on
death certiﬁcates of ICD-9 codes 410–
412, 414, 429.9, 798.1, and 798.2 or
ICD-10 codes I210–I214, I219–I229,
I236, I240–I249, I250–I259, I46.1,
R960, and R961).
Strokewasdeﬁnedbysuggestivenec-
ropsy ﬁndings, clinical records for hospi-
talizedpatients,orICD-9codes430–434
and 436–438 (excluding 437.4–437.8)
or ICD-10 codes I619–I639, I64, I670–
I679, I688, and I690–I698.
Other cardiovascular deaths were
similarly deﬁned. The applicable ICD-9
codes were 401–405, 426–428, and
429.1–429.9 and ICD-10 codes were
I10–I110, I50–I52, I440–I499, I500–
I509, I250, and I511–I519.
Nonfatal acute myocardial infarction
was diagnosed when patients presented
with chest pain lasting 20 min on ad-
mission, followed by typical changes in
serial electrocardiograms and an abnor-
mal increase in the cardiac enzymes or
troponin value curve.
Unstable angina during follow-up
was diagnosed by the presence of angina
symptoms without an abnormal increase
in the cardiac enzymes or troponin and
with electrocardiographic changes in se-
rial electrocardiograms or when, with or
without electrocardiographic changes,
suggestive symptoms were recorded dur-
ing the event and conﬁrmed by a positive
stress test, with or without isotopic stress
gammagraphy, or a positive coronary an-
giogram (stenosis 70%).
Statistical analyses
Our study was sufﬁciently powered
(90%) to identify a statistically signiﬁ-
cant hazard ratio (HR) 0.80 for type 2
diabetic patients compared with ﬁrst
acute myocardial infarction patients, as-
suming 25% 10-year coronary heart
disease incidence among the latter and a
correlation 0.3 of the type 2 diabetes
variable with potential confounders. The
two groups were approximately equally
represented in the study: 51% diabetic
and 49% myocardial infarction patients.
Differences between myocardial infarc-
tionanddiabeticpatientsat10yearswere
assessed by a 
2 test for categorical vari-
ables and by Student’s t test for continu-
ous variables or the nonparametric
equivalents, as appropriate.
Cox proportional hazards models
were ﬁtted to estimate the adjusted HR of
cardiovascular mortality and coronary
heart disease incidence at 10 years. De-
mographic, comorbidity, clinical, and se-
verity variables that showed at least
marginally signiﬁcant differences (P 
0.10) between type 2 diabetes and acute
myocardial infarction patients, as well as
variables considered important based on
clinical judgment, were included as po-
tential confounders in the multivariate
analyses. Because the two cohorts were
conductedatdifferenttimepoints,there-
sults were adjusted for recruitment year,
and a sensitivity analyses was performed
in 2,260 diabetic patients and 828 acute
myocardial infarction patients recruited
in the same time periods (1993–1998).
We considered tertiles of diabetes dura-
tion, comparing the third tertile versus
the ﬁrst and second together and two
groups of glycemic control (A1C 7%
and 7%) and therapy (diet alone, only
oral drugs, and insulin).
Survival curves were estimated with
the Kaplan-Meier method and compared
by Mantel-Cox statistics. Calculations
were made with R (2.6.2 package; The R
Foundation for Statistical Computing,
Free Software Foundation, Boston, MA).
RESULTS— The study included
2,260 type 2 diabetic patients and 2,154
ﬁrst acute myocardial infarction patients
whosurvived28daysaftersymptomonset.
Baseline characteristics of patients are
shown in Table 1. Acute myocardial infarc-
tion patients were younger and less fre-
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women, hypertensive, and dyslipidemic.
The incidence rate for all event types
was signiﬁcantly worse among acute
myocardial infarction patients, except for
stroke death and unstable angina (Table
2). These differences held after adjust-
ment for sex, age, and baseline dyslipide-
mia, hypertension, and recruitment year.
These ﬁndings were similar in both sexes,
except for unstable angina: diabetic
women had a signiﬁcantly lower risk.
Figure 1 shows the Kaplan-Meier
curves of cardiovascular mortality and
coronary heart disease incidence, respec-
tively, comparing myocardial infarction
patients with diabetic patients stratiﬁed
by duration of type 2 diabetes, A1C, and
therapy.Alltype2diabetesstratahadsig-
niﬁcantly lower risk of both end points
thanacutemyocardialinfarctionpatients.
Allsubgroupsofdiabeticpatientshad
signiﬁcantly lower risk of both composite
endpointsthantheiracutemyocardialin-
farction counterparts (Table 3). Patients
with type 2 diabetes receiving insulin
therapy, with 8 years of disease dura-
tion and A1C 7% were at signiﬁcantly
higher risk of coronary heart disease inci-
dence or cardiovascular mortality than
were those receiving dietary therapy
alone or only oral drugs, with 8 years of
evolution and A1C 7%, respectively.
Other cutoff points of A1C (6.5 vs.
6.5% and 6.5, 6.5–7.5, and 7.5%)
showed similar HRs for cardiovascular
mortality and coronary heart disease inci-
dence. At the cutoff point 6.5 vs.
6.5%, the HR for cardiovascular mor-
tality was 0.16 (95% CI 0.10–0.27) and
0.23 (0.17–0.32) and for coronary heart
disease incidence was 0.34 (0.25–0.45)
and 0.44 (0.36–0.53), respectively. For
the cutoff points 6.5, 6.5–7.5, and
7.5%, the HR for cardiovascular mor-
tality was 0.16 (0.10–0.27), 0.22 (0.14–
0.36), and 0.24 (0.16–0.35) and for
coronaryheartdiseaseincidencewas0.34
(0.25–0.45),0.37(0.28–0.50),and0.48
(0.38–0.60), respectively.
Sensitivity analyses produced similar
results. For example, the adjusted HR for
10-year coronary heart disease incidence
and cardiovascular mortality was 0.53
(95% CI 0.42–0.67) and 0.30 (0.20–
0.44) and 0.24 (0.17–0.34) and 0.23
(0.12–0.44) in men and women, re-
spectively.
CONCLUSIONS — The results of
our study indicate that type 2 diabetic pa-
tients without previous coronary heart
disease not only have lower 10-year car-
diovascular mortality but also have lower
coronary heart disease incidence than
ﬁrst acute myocardial infarction patients
without diabetes. These differences held
after adjustment for potential confound-
ers and in subgroups of diabetic patients.
Results of previous studies may have
found similar cardiovascular event rates
due to differences in prognosis. In some
cases,thepopulation-baseddiabetessam-
plesincludedonlypatientsreceivingdrug
treatment, which would exclude up to
Table 1—Baseline characteristics in non–coronary heart disease type 2 diabetic patients
compared with nondiabetic ﬁrst acute myocardial infarction survivors
Type 2 diabetes AMI P value
n 2,260 2,154
Sex (women) 1,219 (53.9) 309 (14.3) 0.001
Age (years) 61.8  8.4 59.3  10.5 0.001
Risk factors
Dyslipidemia* 1,156 (53.9) 806 (40.9) 0.001
Hypertension* 1,334 (59.9) 909 (43.5) 0.001
Smoking 282 (14.4) 57 (11.4)† 0.105
A1C‡ 7.5  1.7 — —
A1C 7%‡ 821 (46.6) — —
Type 2 diabetes duration in years
(median, quartiles) 5.0 (3.0–10.0) — —
Therapy type 2 diabetes*
Diet alone 586 (27.8) — —
Only oral drugs 1,030 (48.9) — —
Insulin 416 (19.7) — —
Oral drugs and insulin 75 (3.6) — —
Non-Q wave myocardial infarction — 436 (20.3) —
Follow-up in days (median, range) 3,452 (142–3,653) 2,597 (32–3,653) —
Data are n (%) or means  SD unless speciﬁed otherwise. AMI, acute myocardial infarction. *Some missing
valuesinthesevariables(5%).†Evaluatedinasampleof499patientsat6months.‡Includedonlypatients
with A1C: fructosamine alone was used in 497 (22%) patients.
Table 2—Incidence rate and adjusted HR of different cardiovascular end points at 10 years for initially non–coronary heart disease diabetic
patients compared with nondiabetic ﬁrst acute myocardial infarction survivors in all participants and by sex
Type 2 diabetes AMI
HR (95% CI)
All participants Men Women
n 2,260 2,154
All-cause death 289 (12.8) 482 (22.4)* 0.39 (0.32–0.46) 0.44 (0.36–0.54) 0.28 (0.20–0.39)
Coronary death 41 (1.8) 206 (9.6)* 0.12 (0.08–0.18) 0.16 (0.10–0.25) 0.09 (0.05–0.17)
Stroke death 24 (1.1) 27 (1.3) 0.66 (0.34–1.27) 0.64 (0.32–1.31) 0.82 (0.09–7.33)
Cardiovascular mortality 99 (4.4) 280 (13.0)* 0.22 (0.17–0.28) 0.26 (0.19–0.36) 0.16 (0.10–0.26)
Unstable angina 184 (8.1) 145 (6.7) 0.95 (0.74–1.23) 1.24 (0.93–1.66) 0.46 (0.29–0.72)
Nonfatal myocardial infarction 126 (5.6) 175 (8.1)* 0.59 (0.45–0.77) 0.72 (0.53–0.98) 0.38 (0.24–0.61)
Fatal or nonfatal myocardial infarction 161 (7.1) 349 (16.2)* 0.33 (0.27–0.41) 0.41 (0.32–0.53) 0.22 (0.16–0.32)
Coronary heart disease incidence† 296 (13.1) 475 (22.1)* 0.43 (0.36–0.51) 0.54 (0.45–0.66) 0.28 (0.21–0.37)
Dataaren(%)orHR(95%CI).Allmodelsareadjustedforsex,age,recruitmentyear,andbaselinedyslipidemiaandhypertension.AMI,acutemyocardialinfarction.
*P  0.001. †Unstable angina or fatal or nonfatal AMI.
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(3–5). In several cohorts of diabetic pa-
tients from Finland, Scotland, and U.S.
selected irrespective of treatment status,
patients with myocardial infarction had
more events than those with diabetes (6–
10). In our study the results suggest that
diabetic patients receiving insulin or oral
drugtreatmentmayhaveaworseprogno-
sis at 10 years than those treated with diet
alone. However, diabetic patients treated
with any of these modalities had signiﬁ-
cantly lower risk than myocardial infarc-
tion patients.
Duration of diabetes was a determi-
nant of cardiovascular outcomes in our
study, which concurs with other reports
(7,11,16). Our cut point (third tertile)
was 8 years; other authors found that
twice this evolution time (16 years) was
required to worsen prognosis at 25 years
(11).
Patients with A1C 7% had worse
prognosis. Diabetic patients in our series
had lower levels of mean A1C at baseline
than those included in the intensive
branch of the UKPDS, 7.5 vs. 8.1%, re-
spectively (14). Despite differences in
study design, our results support the re-
lationship reported by the UKPDS be-
tween high levels of A1C and worse
prognosis. The UKPDS approach is prob-
ably more realistic and correct than the
stricter targets (A1C 6.5%) proposed in
some intervention studies (20) that did
not ﬁnd signiﬁcant differences or an in-
creased number of cardiovascular events
in the more intensive intervention arm.
Some studies with stricter targets have
shown the important role of hypoglyce-
mia episodes in the poor prognosis of pa-
tients randomly assigned to intensive
treatment (21).
We found that incidence of unstable
angina was similar in men with myocar-
dial infarction and in men with diabetes,
but lower in diabetic women than in their
myocardial infarction counterparts. Mor-
tality due to stroke was similar in both
groups of patients and in both sexes. This
observation adds to the existing contro-
versy, with some authors ﬁnding positive
(3,11) and some negative (5,7) differ-
ences. The low number of events, due to
theagerangeselectioninourstudyandto
thefactthatonlyfataleventswereconsid-
ered, hampers a more conclusive result.
Our ﬁndings, taken together with the
oppositeobservationinsomehighcardio-
vascularmortalitycountries(3–5)andin-
termediate observations in central-
western Europe (6) and the U.S. (7),
suggest that geographic variation exists.
In Europe, the south-to-north gradient is
persistently observed in myocardial in-
farction incidence and mortality rates.
The paradox of high cardiovascular risk
factor prevalence that contrasts with rela-
tively low acute myocardial infarction in-
cidence rates has been described in Spain
(17). Our ﬁndings also support such a
gradient: the risk of fatal and nonfatal
Figure 1—Free of cardiovascular mortality (panel 1) and free of coronary heart disease (panel 2) survival curves among initially non–coronary
heartdiseasediabeticpatientscomparedwithnondiabeticﬁrstacutemyocardialinfarction(AMI)survivors.A:Accordingtotimeofevolutionoftype
2diabetes(cutpoint8years).B:AccordingtoA1Clevels(cutpoint7%).C:Accordingtodiabetestreatment(dietalone,onlyoraldrugs,orinsulin).
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was 0.33 (95% CI 0.27–0.41); in similar
cohorts, it was 0.42 (0.33–0.54) in the
U.K.(6)and0.69(0.54–0.88)inFinland
(8). Therefore, primary prevention mea-
sures may need to be adapted to the par-
ticularities of cardiovascular and diabetes
diseases by country or region.
Characteristics and limitations of
the study
We have shown that lipid proﬁle and
blood pressure diagnosis and control im-
proved between 1995 and 2005 in the
region we studied (22). Our sample of
myocardial infarction and diabetic pa-
tients is population-based in a region of
northeast Spain, where risk factor preva-
lenceandmyocardialinfarctionincidence
and mortality are well studied by the
REGICOR group (23). Over the fol-
low-up period, many improvements
occurred simultaneously in the
managementofbothacutemyocardialin-
farction and type 2 diabetes, which may
haveinﬂuencedtheoutcomes.InSpain,a
decrease in 28-day and 1-year mortality
between 1995 and 2000 has been associ-
ated with increased use of reperfusion
strategies and medical therapies (23).
These changes were paralleled by intensi-
ﬁed management of patients’ cardiovas-
cular risk factors and glycemic targets,
following the UKPDS results (14) and in-
ternational recommendations (American
Diabetes Association and European Asso-
ciation for the Study of Diabetes) in pri-
mary care centers within the GEDAPS
network. The proportion of diabetic pa-
tientswhosmokedwasverysimilartothe
proportion of smokers at 6 months after
the index event that was reported in a
sample of the acute myocardial infarction
patients. Finally, asymptomatic myocar-
dial infarction is known to occur to a
greater degree in patients with diabetes
than in the general population. In our
study we did not undertake a systematic
screening procedure to rule out silent
events.
Clinical implications of our study
Type 2 diabetes is on the increase in de-
veloped countries, a trend related to the
epidemics of obesity observed in the past
two decades. For example, in the U.S. be-
tween 1994–1995 and 2003–2004, the
annual incidence of diabetes increased by
23% and prevalence by 62% in individu-
als 65 years (24). The economic and
clinical practice consequences of consid-
ering diabetic patients, who represent
10% of the adult population in devel-
oped countries, for secondary prevention
therapiesareveryimportant:beneﬁtsand
effectiveness must be assessed and bal-
anced, particularly in regions with low
coronary heart disease incidence and
mortality.
Type 2 diabetes is not a coronary
heart disease equivalent for cardiovascu-
lar risk in the region studied. In fact, this
equivalence also has not been found in
countries with high cardiovascular risk
(6–10). Although patients with diabetes
are at higher risk than the general nondi-
abetic population (7), individual cardio-
vascular risk scores are required before
implementation of the level of treatment
(statins, antiplatelet therapy, and intensi-
ﬁcation of hyperglycemia treatment) that
has been shown to be useful in high-risk
patients (25).
Our study conﬁrms that type 2 dia-
betic patients initially free of coronary
heart disease are at lower adjusted 10-
year cardiovascular mortality and coro-
nary heart disease incidence risk than
patients with a ﬁrst acute myocardial in-
farction without diabetes. Our ﬁndings
also contribute to showing that length of
diabetes, type of treatment, and glycemic
control should be taken into account in
future studies on prognosis of patients
with type 2 diabetes initially free of coro-
nary heart disease.
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A1C 7% 0.25 (0.18- 0.35)†‡ 0.46 (0.37–0.57)†‡
Diabetes treatment
AMI patients 1 (reference) 1 (reference)
Diet alone 0.15 (0.09–0.26)† 0.34 (0.26–0.46)†
Only oral drugs 0.20 (0.14–0.29)† 0.42 (0.34–0.52)†
Insulin 0.36 (0.24–0.54)†‡ 0.56 (0.43–0.72)†‡
Data are HR (95% CI). AMI, acute myocardial infarction. *Unstable angina or fatal or nonfatal AMI. †P 
0.05 compared with reference category (myocardial infarction patients). ‡P  0.05 compared with imme-
diately previous category. All models are adjusted for sex, age, recruitment year, and baseline dyslipidemia
and hypertension.
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